RNAi Field Looks to Late-Stage Clinical Data, Approvals to Regain Pharma Interest | GenomeWeb

Though the RNAi field was shaken in late 2010 and early 2011 by the decisions of two major pharmaceutical players to drop their in-house development of oligonucleotide medicines, industry insiders saw a modest renewal of big pharma's interest in the gene-silencing technology in 2012.

However, concerns that RNAi won't live up to its potential remain, making solid clinical demonstrations of its therapeutic utility and even regulatory approvals a must before it will be embraced as warmly as it had in previous years, they said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Wired's Sarah Zhang writes that the fight over who developed the CRISPR/Cas9 genome editing tool first underscores the history of parallel discoveries in science.

Recent research indicates that the benefit of having a number of scientists all living and working in a certain area is eroding.

Tomas Lindahl, Paul Modrich, and Aziz Sancar share this year's Nobel Prize in Chemistry for their studies of DNA repair mechanisms.